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Abstract We screened a chemical library of 2000 compounds
for inhibitors of hepatitis C virus (HCV) serine proteinase using
an in vitro screening method measuring the hydrolysis of the
peptide substrate. Three compounds were found to be the most
potent inhibitors (IC506 1035 M). Two of them had a similar
structure, that of halogenated benzanilide, and were not
inhibitory for common serine proteinases. They inhibited the
enzyme non-competitively with the substrate. Together with the
result of the analogous compounds in the chemical library, the
presumed structural requirements of the inhibition are pointed
out.
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1. Introduction
Hepatitis C virus (HCV) is an etiological agent of non-A
non-B hepatitis. The amino acid sequence deduced from
cDNA cloned in recent years has revealed that the virus is
closely related to the Flaviviridae [1^4]. The polyprotein gen-
erated from the HCV genome is predicted to be organized
as 5P-C-E1-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3P. Two
HCV viral encoding proteinases have been identi¢ed:
Cpro-1 and Cpro-2 [5]. The latter is the trypsin-like serine
proteinase and is located at the N-terminal one-third of
NS3, whereas the former is thought to be a metalloproteinase
which is responsible for the cleavage at the NS2/NS3 junction.
Since viral proteinases are indispensable for virus propaga-
tion, they are good targets for antiviral agents. For screening
of viral proteinase inhibitors, a rapid and sensitive assay of
enzyme activity is required. In a previous article, we reported
an enzyme-linked immunosorbent assay (ELISA) using a fu-
sion protein of the HCV NS3 serine proteinase with maltose
binding protein (MBP-NS3) produced in Escherichia coli, and
a streptavidin-coated microtiter plate which can trap the C-
terminal biotinylated product as well as substrate [6]. The free
amino moieties generated from the C-terminal half of the
product were quanti¢ed. The method has a high throughput
capacity and can be automated, and is thus suited for the
screening of a large number of samples. We report here the
result of the screening of 2000 compounds.
2. Materials and methods
The synthetic compounds included in the HQL Chemical Library
were purchased from Summit Pharmaceuticals International Co. (To-
kyo, Japan).
2.1. Production and preparation of the fused form of NS3 serine
proteinase (MBP-NS345Ps)
The expression vector containing the amino acid sequence of HCV
polypeptide from 985 to 2052, which covered NS3, NS4A, NS4B and
the N-terminus of NS5A, in a plasmid pMAL-c (New England Bio-
labs, Beverly, MA) was constructed by the replacement of the
pMANS2d3X [7] SacII-SalI fragment with that of the entire HCV
non-structural region of the genome followed by PstI deletion. The
expression of the enzyme in E. coli was performed according to the
method reported previously [8]. The enzyme was puri¢ed by a⁄nity
puri¢cation carried out as reported [8], and then chromatographed on
a Hi-Trap Sepharose column followed by gel ¢ltration with a Seph-
acryl S-300 column. The purity of the enzyme was found to be more
than 70% by SDS-polyacrylamide gel electrophoresis analysis quanti-
¢ed with a Personal Densitometer (Molecular Dynamics, Sunnyvale,
CA).
2.2. HCV serine proteinase assay
The peptide substrates Ac-Gly-Glu-Ala-Gly-Asp-Asp-Ile-Val-Pro-
Cys-Ser-Met-Ser-Tyr-Thr-Trp-Thr-Lys-Biotin (AcP17Bio) and Dns-
Gly-Glu-Ala-Gly-Asp-Asp-Ile-Val-Pro-Cys-Ser-Met-Ser-Tyr-Thr-Trp-
Thr-OH (Pep5) were obtained from the Peptide Institute Co. (Osaka,
Japan) and dissolved in DMSO. The standard enzyme reaction for
ELISA was performed as follows: MBP-NS345Ps 80 Wg/ml in a bu¡er
consisting of 50 mM Tris-HCl (pH 7.8), 5 mM CaCl2, 10 mM DTT
and 30 mM NaCl was preincubated with DMSO as control or with
inhibitors dissolved in DMSO for 15 min at 37‡C. The reaction was
started by addition of the AcP17Bio solution at a ¢nal concentration
of 86 WM (5% ¢nal DMSO concentration). The reaction was pro-
longed for 30 min and then quenched by addition of three volumes
of DMSO. The reaction for the HPLC analysis was done using Pep5
at a 2% DMSO concentration for 10 min, and stopped by addition of
5 N NaOH.
2.3. Proteinase assay
The proteinases were purchased as follows: chymotrypsin (bovine
pancreas, Wako Pure Chemicals, Osaka), factor Xa (bovine plasma,
Takara Shuzo, Otsu, Japan), kallikrein (human urine, Funakoshi,
Tokyo), plasmin (human plasma, Funakoshi), K-thrombin (bovine
plasma, Sigma Chemicals, St. Louis, MO), and trypsin (porcine pan-
creas, Wako). The enzyme assay was performed as follows. Chymo-
trypsin 1 unit/ml was preincubated with a sample at 37‡C for 10 min
in a reaction mixture consisting of 50 mM Tris-HCl at pH 8.0 and
2 mM CaCl2 and then reacted with Suc-Ala-Ala-Pro-Phe-MCA
2 Wmol/ml for 10 min. Factor Xa 1 Wg/ml was preincubated at 37‡C
for 20 min and then reacted with Z-Pyr-Gly-Arg-MCA. Kallikrein
1 unit/ml was preincubated at 37‡C for 10 min and then reacted
with Z-Phe-Arg-MCA 100 nmol/ml for 20 min. Plasmin 12 pKcat/ml
was preincubated at 37‡C for 15 min and then reacted with Boc-Glu-
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Lys-Lys-MCA 200 nmol/ml for 20 min. Thrombin 10 units/ml was
preincubated at 25‡C for 15 min and treated with Boc-Val-Pro-Arg-
MCA 400 nmol/ml for 20 min. Trypsin 5 units/ml was preincubated
with 25‡C for 15 min and then treated with Bz-Phe-Val-Arg-pNA for
20 min. The enzyme reaction was quenched by addition of 1% TCA
and £uorescence (excitation 380 nm, emission 460 nm) or absorbance
(405 nm) was then measured.
2.4. ELISA procedure
The ELISA procedure except for the coloring reaction was auto-
matically performed according to the method previously reported [6]
using a Biomek 1000 Automated Laboratory Workstation (Beckman
Instruments Inc., Fullerton, CA).
3. Results and discussion
The enzyme used in this study was expressed as a fusion
protein of MBP and HCV non-structural protein domain con-
sisting of the amino acid sequence from residue 985 to 2052 in
E. coli. The expressed protein was expected to be auto-cleaved
at the NS3-NS4A, NS4A-NS4B and NS4B-NS5A junctions to
produce MBP-NS3, NS4A, NS4B and the N-terminal part of
NS5A. The major protein isolated by a⁄nity chromatography
for MBP had a molecular weight of about 120 kDa as judged
from native polyacrylamide gel electrophoresis. This protein,
designated MBP-NS345Ps, was found to be a complex of the
MBP-NS3 (110 kDa) and NS4A (6 kDa) proteins, since it
reacted with the anti-MBP, -NS3 and -NS4A antibodies. Fur-
thermore, a protein signal of about 6 kDa which reacted with
the anti-NS4A antibody was found in SDS-polyacrylamide gel
electrophoresis analysis. This result con¢rmed that auto-cleav-
age at NS3-4A and NS4A-4B had occurred and that the free
NS4A was bound to the NS3. In the case of the enzyme
preparation we reported previously, MBP-NS3-4A, which
contained the HCV amino acids 1027^1711, NS4A was cova-
lently linked to NS3 [9]. The catalytic rate (Kcat) of the cleav-
age of Pep5 with MBP-NS345Ps at 37‡C was 15.0. The value
was 12 and three times as high as those of MBP-NS3 alone
and the mixture of the MBP-NS3 and a fragment of the
NS4A, P41 (MBP-NS3/P41) [10], respectively, and was almost
comparable with the mixture of the N-terminal portion of
NS3 (vNS3) and P41 (vNS3/P41) [11]. Unlike vNS3, MBP-
NS345Ps was obtained as a soluble protein at neutral pH.
Furthermore, the enzyme was more thermostable than
MBP-NS3 or MBP-NS3/P41, and the optimum temperature
of the cleavage of Pep5 was found to be 50‡C, whereas those
of the MBP-NS3 and MBP-NS3/P41 were 25‡C and 37‡C,
respectively [10]. This evidence suggests that MBP-NS3
formed a tighter complex with NS4A than with the synthetic
NS4A fragment and the complex had higher proteolytic ac-
tivity. By using this enzyme, we were able to reduce the re-
action time to half and the amount of the substrate to one
quarter of the previous condition [6].
Two thousand synthetic compounds were randomly selected
and screened. The ¢rst screening was performed at 1034 M in
a duplicated enzyme reaction. The reaction mixtures were as-
sayed in duplicate by the automated ELISA. It is expected
that 250 samples could be screened within a week with this
method. The samples which reduced the cleavage to less than
30% of the control were selected and re-screened by HPLC
analysis. After the two-step selection, three compounds, des-
ignated compounds 1, 2 and 3, were selected as the most
e¡ective inhibitors. Table 1 shows the results of the HPLC
analysis of these compounds at concentrations of 1034, 1035,
and 1036 M as well as the IC50 values. As shown in Table 2,
their e¡ect on some serine proteases, including chymotrypsin,
factor Xa, kallikrein, plasmin, K-thrombin and trypsin, were
examined at a concentration of 1035 M, where they reduced
the HCV serine protease activity by more than 50%. A 50% or
greater reduction of the activity of factor Xa and trypsin was
produced by compound 1. The other two compounds did not
inhibit these proteinases e¡ectively. Compounds 2 and 3,
which seemed to be speci¢c inhibitors for HCV serine protein-
ase, were found to have a similarity in chemical structure, that
of benzanilide, as shown in Fig. 1. The structure consisted of
benzoic acid which was substituted with halogen and a
hydroxy or amino group at the meta and ortho positions,
respectively, and aniline whose meta position was chlorinated.
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Fig. 1. The structure of compounds selected from the chemical li-
brary.
Table 1
E¡ect of the compounds selected from the chemical library on HCV serine proteinase
Compound (%) Cleavage IC50
1034 M 1035 M 1036 M U1035 (M)
1 1.9 þ 0.4a 18.6 þ 1.0 81.4 þ 6.4 0.32
2 15.5 þ 6.8 41.9 þ 10.2 85.2 þ 1.1 0.65
3 16.4 þ 7.5 35.6 þ 10.6 106.4 þ 11.9 0.62
aThe values of production of the cleavage product relative to the control are expressed as means þ standard deviations of triplicate assays.
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To examine the e¡ect of substituents on the inhibitory ac-
tivity, compounds with analogous structures in the chemical
library were compared as a reference. Fig. 2 shows the struc-
ture of the reference compounds and the result of the screen-
ing at a concentration of 1034 M. Compound 5 had the same
structural features of 2 and 3 as pointed out above, and so
had 4 though the position of chlorine in the aniline moiety
was para instead of meta, and they were almost as e¡ective as
2 and 3. Compounds 4, 6 and 7 had the same R1 substituent,
and di¡erent substituents in the aniline ring were compared.
The insertion of methylene at the amino moiety (compound 6)
or the replacement of chlorine at the para position with iso-
propyl (compound 7) reduced the inhibitory activity. It seems
that the amino moiety conjugated with a phenyl ring and
chlorine substitution favored the inhibition. Comparing com-
pounds 3, 5 and 8, compounds which had the halogenated
naphthoxy moiety in the aniline ring (compounds 3 and 5)
showed high inhibitory activity, and the replacement of this
moiety with chlorine (compound 8) resulted in a large reduc-
tion of the activity. Similarly, by the replacement of the phe-
nyl sulfamide moiety in benzoyl ring of compound 4 with a
smaller substituent, a hydroxyl group (compound 8), the in-
hibitory activity was also reduced. From these results, com-
mon structural features of compounds 2 and 3, as well as a
large substitution in either the aniline or the benzoyl ring seem
to be required for the inhibitory activity. The style of the
inhibition of compound 3 was studied by Dixon plot as shown
in Fig. 3. Compound 3 was found to be a non-competitive
inhibitor as was compound 2 and their inhibition constant
(Ki) values were estimated to be 3.6 and 2.4 WM, respectively.
The results suggest that these compounds do not bind to the
substrate binding pocket.
Several attempts to seek HCV serine proteinase inhibitors
have been reported recently including mutated NS4A frag-
ments [12] and detergents such as n-octyl-glucoside and
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Fig. 2. The structure of the reference compounds in the chemical li-
brary and the (%) control of the cleavage activity of MBP-NS345Ps
in the presence of these compounds at a concentration of 1034 M.
Fig. 3. Dixon plot illustrating the inhibition of MBP-NS345Ps by
compound 3. MBP-NS345Ps 80 Wg/ml in a bu¡er consisting of 50
mM Tris-HCl (pH 7.8), 5 mM CaCl2, 10 mM DTT and 30 mM
NaCl was preincubated with compound 3 dissolved in DMSO for
15 min at 37‡C. The reaction was started by addition of Pep5 solu-
tion at a ¢nal concentration of 22 (O), 43 (8) and 86 WM (a) (a ¢-
nal DMSO concentration of 2%). The reaction was prolonged for
10 min and then quenched by addition of 5 N NaOH. The reaction
mixture was analyzed by HPLC.
Table 2
E¡ect of the compounds selected from the chemical library on some serine proteinases
Compound 1 2 3
Chymotrypsin 103.7 þ 4.1a 100.9 þ 8.9 100.9 þ 2.3
Factor Xa 47.0 þ 10.6 85.3 þ 5.1 90.5 þ 17.9
Kallikrein 68.2 þ 1.9 87.5 þ 6.0 84.7 þ 6.7
Plasmin 74.8 þ 3.5 83.2 þ 0.8 92.1 þ 3.4
K-Thrombin 96.3 þ 5.5 97.5 þ 5.6 105.1 þ 7.0
Trypsin 26.7 þ 5.2 97.6 þ 2.5 97.6 þ 2.5
aThe compounds at a concentration of 1035 M were used for the examination. The values of production of the cleavage product relative to the
control are expressed as the means þ standard deviations of 3^6 assays.
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CHAMP [13], which were supposed to prevent binding of
NS3 and NS4A. Variable domain antibody fragments
[14,15] as well as nucleic acid fragments [16] showed speci¢c
a⁄nity for HCV serine proteinase and were inhibitory for the
cleavage activity. Competitive peptidyl inhibitors based upon
the NS5A-5B junction were proposed [17]. However, those
compounds were relatively large in molecular weight. Further-
more, the detergents were not speci¢c, and the peptides and
RNA fragments would be easily subjected to hydrolysis. The
compounds sorted out by the assay were non-peptide com-
pounds with low molecular weight and will be prototypes for
the further development of anti-HCV agents.
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